Efficacy and Safety of MEthylprednisolone Administered Intravenously for the Treatment of Patients With Active AnkyLosing spondyLitis (METALL)

Saratov State Medical University

Status and phase

Unknown

Phase 2

Conditions

Ankylosing Spondylitis

Treatments

Drug: Methylprednisolone

Study type

Interventional

Funder types

Other

Identifiers

NCT01790022

METALL 2012

Details and patient eligibility

About

In this study, efficacy of methylprednisolone in reduction of signs and symptoms (back pain, stiffness, joint pain and swelling) of active ankylosing spondylitis (AS) will be investigated. It is expected, that a single dose of methylprednisolone 500 mg given intravenously at baseline will lead to a rapid reduction of symptoms of active AS, which can be seen already 2 weeks after drug administration.

Enrollment

20 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age of ≥18 years.
Definite diagnosis of AS according to the modified New York criteria.
History of an inadequate response to ≥2 nonsteroidal antiinflammatory drugs (NSAIDs) taken for at least 2 weeks each or NSAIDs intolerance.
Active disease as defined by the Bath Ankylosing Spondylitis DIsease Activity Index (BASDAI) value of ≥4 at screening despite concomitant treatment with an NSAID or without NSAIDs in case of intolerance.

Exclusion criteria

The female subject is pregnant or lactating.
Patients with other chronic inflammatory articular disease or systemic autoimmune disease.
History of inadequate response to previous anti-tumour necrosis factor (TNF) α therapy.
Treatment with any other investigational drug within 4 weeks of 5 half-life of the drug (whichever is longer) prior to baseline.
Treatments with disease modifying anti-rheumatic drugs (DMARDs) other than methotrexate within 4 weeks prior to screening (8 weeks for leflunomide or 4 weeks with a standard cholestyramine wash-out).
Treatment with intravenous, intramuscular or intraarticular/periarticular steroids within 4 weeks prior to screening.
History of oesophageal, gastric, duodenal or intestinal ulceration, clinically relevant gastrointestinal bleeding.
History of or current signs of coronary heart disease, myocardial infarction, stroke or transient ischemic attack, peripheral arterial thrombotic events.
Congestive heart failure (NYHA III-IV)
Uncontrolled arterial hypertension.
History of diabetes mellitus.
History of glaucoma.
Major surgery within 12 weeks prior to screening.
Evidence of any other severe uncontrolled gastrointestinal, hepatic, renal, pulmonary, cardiovascular, nervous or endocrine disorders.
Any active current viral, bacterial or fungal infection, a history of recurrent clinically significant infection, infections requiring treatment with antibiotics within 4 weeks prior to baseline.
History of chronic infection with hepatitis B or C, history of HIV infection.
Primary or secondary immunodeficiency.
Any other conditions making the patient unsuitable in the opinion of the investigator for the participation in the current study.